Antibiotic Drug Market

Antibiotic Drugs Market Outlook (2023 to 2033)

The global antibiotic drugs market was valued at USD 43.6 billion in 2022 and is expected to reach USD 64.9 billion by 2033. The sales of antibiotic drugs are set to gain traction over the forecast years with a CAGR of around 3.7%.

Attributes	Key Statistics
Market Value (2022)	USD 43.6 billion
Market Value (2023)	USD 45.0 billion
Market Value (2033)	USD 64.9 billion
Estimated Growth (2023 to 2033)	3.7 % CAGR
Share of Top 5 Countries	66.2%

Key Market Highlights

Emergence of Infectious Diseases

• Medication containing antibiotics is now much more widely available. The efficacy of antibiotic drugs for urinary tract infections and several skin conditions has led to the development of generic versions. Sales of antibiotic drugs rose sharply due to the increase in infectious diseases such as streptococcal pharyngitis and bronchitis during the pandemic, which led industry experts to focus on effective therapy and medication that can fight against bacterial and parasitic illnesses.
• Hospital admissions always raise the risk of healthcare-associated infections (HCAIs), which increases the need for antibiotics. Therefore, the heavy use of antibiotics in ambulatory surgical centers and renal disease facilities has pushed the antibiotic drug market growth.
• In an investigation conducted by the Qatar Biomedical Research Center and published in August 2022, according to their study on ICU patients in 88 different countries, 70% of hospitalized patients took at least one antibiotic during their acute stay, and 54% of this group develop a subsequent bacterial infection that requires antibiotic therapy. To avoid further infection-related consequences, such as severe acute respiratory distress syndrome (ARDS) and multi-organ failure, the WHO advised giving antimicrobial therapy to patients with severe illness.

Expansion in Product Portfolio

• Leading biotechnology businesses are introducing new genetic products and broadening their product lines, which is anticipated to raise the revenue of antibiotic producers indirectly.
• Biotechnology businesses increased their investment in research and development due to the demand for new classes of antibiotics to support cutting-edge medical procedures to address the multidrug-resistant impact and rising incidence of bacterial resistance.
• To maintain a pipeline of new antibiotics, biotechnology companies are thus motivated to produce improved antibiotic molecules. Companies now have the chance to expand their market presence thanks to this.

2017 to 2022 Market Demand Outlook for Antibiotic Drugs Compared to 2023 to 2033 Forecast

The antibiotic drugs market exhibited a CAGR of 2.9% between 2017 and 2022. In 2022, the global market for anti-infective medicines accounted for around USD 76.7 billion, of which antibiotics have a share of USD 43.6 billion.

Attributes	Key Statistics
Market Value (2021)	USD 42.3 billion
Estimated Growth (2017 to 2022)	2.90 % CAGR

The rising antibiotic treatment for bacterial infections to prevent them from spreading has spurred the global demand for antibiotics. In India, the percentage of single antibiotics consumption is around 4.1 billion, according to the National Library of Medicine. The WHO report on antibiotic usage surveillance, published in 2018, examined data from 65 countries. As determined by daily dosages per 1,000 inhabitants with a rate of 64.4, Mongolia had the most prominent consumption. At 4.4, Burundi received the lowest score. The most popular antibiotics consumed were amoxicillin and amoxicillin/clavulanic acid.

Factors Restraining the Demand for Antibiotic Drugs

New entity development is more time- and money-consuming; it can take a substantial financial burden and several years to complete. Therefore, it is anticipated that the market for antibiotics can be hampered by the high cost of medication research and the rigorous regulatory approval process.

Adverse effects might result from inadequate knowledge of antibiotic administration and the indiscriminate use of antibiotics for minor infections. As a result, it is anticipated that the growing demand for antibiotics will be hampered by the increased side effects brought on by the emergence of resistance and other adverse side effects. For instance, taking a quinolone antibiotic and a systemic corticosteroid may cause tendon injury.

Antibiotic-resistant microorganisms have emerged due to improper antibiotic use and misuse. Antibiotics' potential danger goes beyond the development of antimicrobial resistance, and excessive use of them is linked to adverse consequences on patients, which are particularly obvious in critically ill patients in intensive care units.

Antibiotics are frequently administered to treat illnesses or symptoms that don't react to them or are likely to go away on their own. Additionally, inappropriate or inadequate antibiotics are administered for some bacterial illnesses. Therefore, these factors contribute to the restraint of the growth of the antibiotic drugs market.

Country-wise Insights

Top Countries	CAGR
United States	12.1%
China	8.2%
India	6.1%
United Kingdom	4.3%
Germany	3.1%

The United States is the Leading Market for Antibiotic Drugs

The United States is dominating the antibiotic drugs market with a share of 12.1%. The market was valued at USD 5.1 billion in 2022.

The American healthcare system is renowned for its high costs and sophisticated infrastructure. The United States government and regulatory authorities are implementing a variety of cost-effective healthcare schemes to curb catheter-associated UTIs and other infectious diseases. Furthermore, there is a growing need for antibiotics as a result of the increased occurrence of ventilator-associated infections.

According to the Centers for Disease Control and Prevention (CDC), more than 2.8 billion antimicrobial-resistant illnesses occur in the United States each year, resulting in more than 35,000 deaths. The United States government is undertaking several preventative and infection control strategies to reduce the number of illnesses and fatalities caused by antibiotic-resistant bacteria. The United States market for antibiotics is now experiencing significant growth opportunities.

China is an Emerging Market for Antibiotic Drugs

China is an emerging antibiotic drug market with a market share of 8.2%, with a valuation of USD 3.4 billion in 2022.

The pharmaceutical market in China is the second-leading in the world and is further expanding rapidly. China's OTC pharmaceutical business is still enticing, with a sizable market share. According to OEC (Observatory of Economic Complexity), China was the world's top supplier of antibiotics in 2020, with shipments amounting to USD 3.98 billion.

The healthcare industry in China has expanded significantly, allowing it to transition from a base for the production of pharmaceuticals to a vital research and development center. As a result, China has strengthened its position as a strategic player in the global pharmaceutical industry, acting as a foundation for increasing research and development while also functioning as a consumer nation. With all these factors combined, the market of antibiotic drugs in China is one of the emerging and lucrative markets.

High Prevalence of Infectious Diseases Driving the Antibiotic Drugs in India

India is an emerging market and accounted for a market share of more than 6.1% in 2022.

In recent years, small and leading biopharmaceutical businesses in India have relied on the contract research organization (CRO) industry to supply research services to their R&D operations. However, as the majority of medicines in the pipeline are predicted to reach the end stage and be commercialized by the end of the decade, it is anticipated that the need for antibiotics will rise.

Due to the existence of multiple government-funded medical and pharmaceutical institutions with state-of-the-art equipment, clinical trials and research are now a significant industry in India. For multi-centered clinical studies, these facilities are appropriate. These factors are making India one of the new emerging antibiotic drug markets.

Category-wise Insights

Penicillins Accounted for the Prominent Share of 27.9% in 2022

Penicillin-based products dominate the market for antibiotics worldwide. The penicillin antibiotics segment is anticipated to rule the worldwide antibiotics market throughout the forecast period.

Top Product Type	Penicillins
CAGR	3.6%

The acceptance of penicillin as a first-line antibiotic therapy and the rising demand for antibiotics to treat various bacterial infections are expected to increase the need for penicillin globally.

Gastrointestinal Infections Indication for Antibiotic Drugs is Highly Sought After

People typically contract an infection by contacting infected individuals, eating or drinking contaminated food or water (sometimes called food poisoning), or handling contaminated objects like cutlery, taps, toys, etc.

Top Indication	Gastrointestinal Infections
CAGR	3.5%

This results in an increased prevalence of gastrointestinal infection or gastroenteritis. Hence, it had a market share of 26.0% in 2022.

Parenteral Route of Administration Projected Prominent Growth

The parenteral route of drug administration occupied 68.6% of global market share in 2022. Intravenous (IV), intramuscular (IM), and subcutaneous parenteral methods are the most significant and often utilized parenteral routes (SC).

Top Route of Administration	Parenteral
CAGR	3.5%

For medications with limited GIT absorption and medicines like insulin that are unstable in the GIT, the parenteral route of drug administration is the preferred method.

Competitive Landscape

To expand their product offerings and boost the competitiveness of their companies, the key market participants focus on introducing several effective medications and winning regulatory body clearance. Additionally, businesses are increasingly focusing on expanding their business globally by setting up new labs and facilities to enhance their market presence.

Recent Development

• In October 2023, Venus Remedies launched Elores, an antibiotic medicine in Ecuador.
• In January 2022, Alembic Pharmaceuticals announced that its ANDA for Doxycycline Hyclate Delayed-Release Tablets has received FDA approval. The medication is used to prevent the growth of bacteria.
• The biotechnology business NetVation DL Medicine, which specializes in discovering and developing innovative therapeutic candidates, announced its research partnership with Pfizer Inc. in May 2020.

Scope of the Report

Attribute	Details
Forecast Period	2023 to 2033
Historical Data Available for	2017 to 2022
Market Analysis	USD million for Value
Key Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; the Middle East & Africa
Key Countries Covered	United States, Canada, Brazil, Mexico, Argentina, Germany, United Kingdom, France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, South Africa, North Africa, and GCC Countries.
Key Segments Covered	Drug Class, Indication, Route of Administration, Distribution Channel, and Region
Key Companies Profiled	Abbott Laboratories; AbbVie; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Merck & Co. Inc.; Mylan N.V.; Novartis International AG (Sandoz); Sanofi; Teva Pharmaceutical Industries Ltd.; Melinta Therapeutics; Pfizer Inc; Basilea Pharmaceutica Ltd.; Tetraphase Pharmaceuticals; Paratek Pharmaceuticals, Inc.; Nabriva Therapeutics plc; Spero Therapeutics
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing	Available upon Request

Antibiotic Drugs Market by Category

By Drug class:

• Penicillins
• Fluoroquinolones
• Cephalosporins
• Macrolides
• Others

By Indication:

• Dermatological Infections
• Respiratory Infections
• Urinary Tract Infections
• Ear Infections
• Gastrointestinal Infections
• Others

By Route of Administration:

• Oral
• Parenteral

By Distribution Channel:

• Retail pharmacies
• Hospital pharmacies
• Online pharmacies

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• The Middle East & Africa (MEA)

Frequently Asked Questions

How Much is the Antibiotic Drugs Market Currently Worth?

The global market is likely to be worth USD 45 billion in 2023.

What is the Sales Forecast for the Antibiotic Drugs Market through 2033?

The market is expected to reach USD 64.9 billion by 2033.

Which is the Lucrative Region for the Antibiotic Drugs Market?

North America holds 23.9% of the global market in 2022, with the United States being the leading contributor.

What are the Key Market Statistics in China?

China's market is offering lucrative growth, with a market share of 8.2% in 2022.

What are the Top 5 Countries Driving Demand for the Antibiotic Drugs Market?

The United States, China, India, the United Kingdom, and Germany are the top 5 countries.

What was the Last 5 Year’s CAGR Value for the Antibiotic Drugs Market?

From 2017 to 2022, the market for antibiotic drugs expanded at the rate of 2.9%.

Which are the Leading Companies in the Antibiotic Drugs Market?

Pfizer, Sanofi SA, AbbVie Inc. (Allergan plc), Teva Pharmaceuticals, GlaxoSmithKline plc, Novartis AG, Abbott Laboratories, etc.